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he Use of Cardiovascular
agnetic Resonance to
dentify Adverse
ardiac Prognosis
n Important Step in Reducing
mage-Related Heath Care Expenditures*
. Gregory Hundley, MD
inston-Salem, North Carolina
dvances in cardiovascular (CV) imaging have contributed
o the marked reductions observed in CV mortality over the
ast 40 years (1). Importantly, however, expenses for CV
maging have outpaced the growth in expenses for other
hysicians’ services over the same timeframe (2). Recently,
oth the government and private insurers have reacted to
his increase in CV imaging-related expenditures by insti-
uting processes to curb imaging procedure utilization (3).
See pages 1225 and 1235
pecifically, the implementation of radiology benefit man-
gers (RBMs) have been utilized to pre-certify CV-related
maging procedures in the fields of cardiovascular computed
omography (CCT) and cardiovascular magnetic resonance
CMR) (4). Often, obtaining qualifying payment for an
maging procedure requires a pre-certification phone call
rom a physician, which takes 30 min and delays health care
elivery. Although RBMs may disallow up to 26% of
maging case requests, additional concerns have been raised
hat as many as 20% to 30% of those performing the
creening procedures may be unfamiliar with both the
iagnostic accuracy and patient suitability for CMR (5).
Physicians are also concerned with growth in health care
xpenditures related to CV imaging. Importantly, however,
hysicians have advocated different means of limiting CV
maging health-related expenditures by focusing on quality
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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30AG21332, and N01-HC-95165.f care (6). Quality is a broad term including several
rocesses that when utilized together may be used to limit
osts by selecting patients for the correct imaging procedure.
uality processes include: 1) identifying the appropriateness
f the referral of a patient in an imaging procedure;
) insuring adequacy of the performance of a procedure;
) reporting procedural results in a timely fashion; and
) often linking results to patient-related outcomes (6).
mportantly, physician societies, such as the American
ollege of Cardiology, rely on evidence-based materials to
evelop criteria, guidelines, and standards that direct
uality-based initiatives (6). Quality measures can be im-
lemented in a fashion to select patients’ suitability for
rocedures without lengthy workflow delays.
Research is utilized to establish the processes for guiding
he development of quality-based initiatives (7). In regards
o CV imaging, this research has several stages including
stablishment of the technical feasibility and safety, deter-
ining the diagnostic accuracy, defining the prognostic
tility, and finally, understanding both the cost-benefit and
atient satisfaction aspects of the procedure. Not perform-
ng all of these steps can, however, lead to increases in
xpenditures. Potentially contributing to escalating health
are expenses related to CV imaging is the fact that this
rocess is often short changed such that the latter stages
prognosis and cost-benefit) of development are not accom-
lished (6). If quality is to be used to facilitate control of
ealth care expenditures related to CV imaging (particularly
CT and CMR), further research is necessary across large
tudy populations, that helps to define the prognostic utility
s well as cost-benefit of these modalities.
To this end, 2 studies presented in this issue of the
ournal, from Korosoglou et al. (8), and Aquaro et al. (9),
ddress the prognostic utility of CMR results in patients
ith chest pain syndromes and individuals with 1,000
remature ventricular contractions (PVCs) in a left bundle
ranch block (LBBB) pattern on 24-h telemetry monitor-
ng. In the first study, Korosoglou et al. (8) studied 1,493
atients who underwent dobutamine CMR stress testing
ncorporating both left ventricular (LV) wall motion and
yocardial perfusion analyses. They then followed these
ndividuals for 2 years and identified 53 major CV events
including 14 cardiac deaths and 39 myocardial infarctions)
ithin the study population. In this relatively large, single-
enter study, dobutamine-induced LV wall motion and
erfusion abnormalities predicted future adverse CV events
fter accounting for established risk factors of CV disease.
Features of this study allow practitioners to draw several
mportant conclusions regarding the use of CV stress testing
o assess cardiac prognosis. Because of the versatility of
MR, the investigators were able to assess LV wall motion
nd perfusion in all the patients during a single exam. This
llowed the investigators to compare the 2 techniques and
etermine when 1 (wall motion or perfusion) should or
hould not be used to supplement the other. The relatively
l
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October 5, 2010:1244–6 CMR and CV Prognosisarge number of study participants also allowed the investi-
ators to reach important conclusions regarding patient
ubgroups and associated comorbidities.
Important conclusions drawn from this study include:
rst, the identification of dobutamine-induced wall motion
bnormalities forecasted CV prognosis in those with or
ithout myocardial perfusion deficits. The converse, how-
ver, was not true, as perfusion assessments only provided
ncremental prognostic information in individuals who did
ot experience an inducible wall motion abnormality during
ntravenous dobutamine. Moreover, the prognostic utility of
hese additional perfusion images occurred only in those
ith existing LV wall motion abnormalities at rest, those
ith known coronary disease, or those with LV hypertro-
hy. Since perfusion assessments require the addition of
adolinium contrast, and contrast is associated with incre-
ental expense and minor risks to participants, the results
f this large study indicate that if individuals with normal
esting LV function experience an inducible wall motion
bnormality during testing, then contrast perfusion need not
e administered since the determinations are not useful in
roviding any increment prognostic information regarding
V risks. The same is true in patients without inducible LV
all motion abnormalities if individuals have a normal LV
jection fraction, no LV hypertrophy, and no existing wall
otion abnormalities at rest.
The data from Korosoglou et al. (8) also indicate when
he addition of contrast will provide incremental benefit for
ssessing cardiac prognosis. As shown in their study, the
mplementation of gadolinium contrast is helpful for iden-
ifying adverse prognosis if a patient does not exhibit a wall
otion abnormality at peak dobutamine, but exhibits a
esting LV wall motion abnormality, known coronary dis-
ase, or LV hypertrophy. The data from this study and
thers (10) raise an interesting question as to whether
obutamine CMR stress perfusion studies should be con-
idered as a first-line dobutamine stress modality (rather
han echocardiography alone with wall motion) in appro-
riately equipped and credentialed centers when patients
xhibit resting LV wall motion abnormalities, coronary
rtery disease, or LV hypertrophy, and there is no contra-
ndication to contrast.
Second, the presence of dobutamine-induced LV wall
otion abnormalities forecasts cardiac prognosis in individ-
als regardless of the pretest probability of coronary artery
isease (low, intermediate, or high). The absence of induc-
ble LV wall motion abnormalities only confers a favorable
V prognosis in those who are at low or intermediate risk.
Finally, the results (positive or negative for ischemia) of
ither wall motion or perfusion stress tests do not add
ncremental information regarding CV prognosis in indi-
iduals with a severely reduced LV ejection fraction at rest.
hus, for individuals with a resting LV ejection fraction of
35%, dobutamine stress testing will only be useful indentifying myocardial ischemia or viability when selecting nndividuals who may be candidates for coronary artery
evascularization procedures to relieve symptoms.
The study by Aquaro et al. (9) is different in that it was
resting CMR exam and is focused on the right ventricle as
pposed to the left ventricle. The study population included
elatively young (average age of 33 years) individuals with
1,000 PVCs in 24 h, of a LBBB morphology with inferior
xis on the 12-lead electrocardiogram. Four hundred and
orty subjects, of which 396 were included in the analysis,
nderwent a resting CMR exam in which right ventricular
RV) regional wall motion, volumes, ejection fraction, and
issue characterization (using determinations of myocardial
at content without gadolinium contrast) were performed.
ll individuals had a normal maximal exercise stress test, a
egative family history for sudden cardiac death, normal
chocardiogram, no hypertension, diabetes, or coronary
rtery disease, and were otherwise not suspected to be at risk
or CV events.
Major (RV dyskinesis, severe RV dilation, or a RV
jection fraction 40%) and minor (RV dilation that was
bove 2 standard deviations but below 4 standard deviations
f normal, RV hypokinesis, or individuals with a RV
jection fraction between 40% and 50%) criteria for arrhyth-
ogenic RV cardiomyopathy were identified in all partici-
ants (11). Importantly, in this study, individuals with 2
f these abnormalities (major or minor) experienced a
ignificant increase in the incidence of a major CV event,
ncluding sudden cardiac death, resuscitated cardiac arrest,
r subsequent defibrillator shocks for ventricular tachycardia
r fibrillation recorded by the defibrillators implanted after
he CMR procedure.
In addition, individuals with none of these factors, even if
here was suspected fatty infiltration of the RV wall, had a
avorable prognosis. The results of this latter study indicate
hat individuals over the age of 20 years with frequent PVCs
f a LBBB morphology should likely undergo a thorough
MR examination of the right ventricle as these individuals
ay be at risk for developing RV cardiomyopathy that could
ead to an adverse CV event. It is important to recognize
hat these abnormalities were not observed on transthoracic
chocardiography; thus, one should not assume a normal
chocardiogram will serve as a surrogate for a CMR study in
hese patients.
What are the limitations to the studies of Aquaro et al.
9) and Korosoglou et al. (8)? First, studies such as these
equire ancillary and physician staffing with expertise in
erformance and interpretation of relatively advanced
MR. This includes management of ventricular arrhyth-
ias, the capability to administer and monitor the effects of
ardiac stress agents, and the ability to react to adverse CV
vents during the procedure. Thus, studies should be per-
ormed in centers with appropriate credentialing and exper-
ise (12). To this end, the Society of Cardiovascular Mag-
etic Resonance, an international society that includes
ardiologists, radiologists, physicists, and biomedical engi-
eers, can provide reference and guidance on training and
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CMR and CV Prognosis October 5, 2010:1244–6rotocols necessary to perform the types of procedures
escribed in these papers.
Second, in both studies, most subjects possessed a rela-
ively regular heart rhythm during their exam. In fact, in the
quaro et al. (9) study, some individuals (number not
isclosed) received antiarrhythmic therapy 1 week prior to
he CMR procedure for the purpose of minimizing PVCs.
t is important to recognize that not all patients may be
ligible for this type of treatment (particularly those in an
cute hospital setting). Recently, high temporal resolution
real-time” (no cardiac gating required) imaging has been
ade available on some vendor platforms (13). Whether
real-time” imaging would be useful in these situations is
ncertain. Finally, certain patients are not well suited for
hese procedures. Currently, this includes individuals with
mplanted devices, such as a pacemaker or defibrillator, or
erromagnetic intracranial metal (14). Also, in patients with
evere renal dysfunction, one avoids administration of gadolin-
um contrast (for myocardial stress perfusion) to avert the risk
f nephrogenic systemic fibrosis (14).
In summary, these 2 relatively large, single-center studies
emonstrate the effective use of CMR in identifying CV
rognosis in 2 groups of patients: those with chest pain
yndromes, and relatively younger individuals with multiple
VCs of a LBBB morphology. Results from large prognos-
ic studies such as these provide important evidence for
irecting the appropriate use of advanced CV imaging
echniques such as CMR, and can direct planning of
dditional research that addresses cost-benefit–related is-
ues. Korosoglou et al. (8) and Aquaro et al. (9) are to be
ommended regarding their research initiatives because it is
esults such as these that help to provide the foundation for
igh-quality health care initiatives that can be used to direct
ndividual patient-care imaging in an increasingly resource-
imited environment.
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